COVID-19

Outside of the loss of human life due to the COVID-19 pandemic, the past two years have greatly affected hospitals, health systems and the way providers deliver care. Healthcare executives are grappling with federal monetary assistance, growing burnout rates, workforce shortages and federal oversight of vaccines and testing. This channel is also designed to update clinicians on new research and guidelines regarding COVID patient treatment strategies and risk assessments.

Thumbnail

A potential new treatment for COVID-19 patients with MIS-C

The medication, originally developed to treat celiac disease, could provide significant relief for young MIS-C patients. 

95% of doctors believe COVID-19 has exposed cracks in the medicine supply chain

Sixty-two percent of those surveyed believe significant reliance on other countries for medicines is among the biggest contributing factor to medicine shortages, according to new survey results.

AstraZeneca COVID-19 vaccine slightly increases risk of blood clots

Researchers emphasized that the benefits of the vaccine still far outweigh the risks. 

With patient safety slipping, CDC and CMS turn focus to more resilient approaches

COVID-19 has led to a quick and steep decline in patient safety across the entire American healthcare system.

COVID-19 vaccine associated myocarditis on short-axis 1.5T MRI images of a 19-year-old man who presented with chest pain three days following the second dose of an mRNA COVID-19 vaccine.

Cardiac MRI sheds new light on vaccine-related myocarditis

Vaccine-associated myocarditis shows an injury pattern on cardiac MRI similar to other causes of myocarditis, but abnormalities are less severe. 

Number of primary care physicians associated with higher COVID-19 vaccination rates

Every 10 additional PCPs per 100,000 people was associated with a 0.3% higher vaccination rate.

Enhanced external counterpulsation may help patients fight against long COVID

The small study included patients with and without coronary artery disease. 

coronavirus COVID-19 vaccine vaccination

FDA postpones meeting on Pfizer COVID-19 vaccine for younger children

Pfizer wants more time to review clinical data on the certain regimens for children six months through four years old.